Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Infection Transmission by Saliva and the Paradoxical Protective Role of Saliva

1.1 SALIVA COMPOSITION AND SECRETION

Saliva is produced by both major (parotid and submandibular and sublingual) and minor (located in the mouth) glands, with different constituents and properties between the two groups. In the mouth saliva is a colorless, odorless, tasteless, watery liquid containing 99% water and 1% organic and inorganic substances and dissolved gases, mainly oxygen and carbon dioxide. Salivary constituents can be grouped into proteins (e.g., amylase and lysozyme), organic molecules (e.g., urea, lipids, and glucose mainly), and electrolytes (e.g., sodium, calcium, chlorine, and phosphates). Cellular elements such as epithelial cells, leucocytes and various hormones, and vitamins have also been detected. The composition of saliva is modified, depending on factors such as secreted amount, circadian rhythm, duration and nature of stimuli, diet, and medication intake, among others.

Despite this heterogeneous composition, from the functional point of view saliva has to be considered as a unique biological fluid, and not as the sum of its biochemical components.

Salivary secretion and maintenance of a film of saliva on oral surfaces is dependent upon nerve-mediated, reflex salivary gland secretion mainly stimulated by taste. The afferent arm is mainly activated by stimulation of chemoreceptors (located in the taste buds) and mechanoreceptors (located in the periodontal ligament). Olfaction, mental processes, and stretch of the stomach are weak stimuli. Impulses affecting secretion depending on the emotional state are carried by afferent cranial nerves V, VII, IX, and X to the CNS salivary nuclei (salivation center) in the medulla oblongata. The efferent part of the reflex is mainly parasympathetic. The cranial nerve VII provides control of the submandibular, sublingual, and minor glands, whereas the cranial nerve IX controls the parotid glands. The flow of saliva is enhanced
by sympathetic innervation, which promotes contraction of muscle fibers around the salivary ducts.\textsuperscript{5} Autonomic nerves also have an important role in both gland development and function.\textsuperscript{6} A dry mouth is a common experience where there is fear.

Saliva may be secreted in the absence of exogenous stimuli, then referred to as the resting or unstimulated salivary flow. In the resting state 70\% of saliva is secreted by the submandibular and sublingual glands. When stimulated, the parotids provide most of the saliva and flow can increase by up to fivefold. On average, in healthy nonmedicated adults, the unstimulated and chewing-stimulated salivary flow rates are about 0.3 and 1.5 mL/min respectively,\textsuperscript{1} but the range is wide and the limits of normality in all age groups and both genders are considerable. The normal daily production of saliva varies from 700 mL to 1.5 L. A decrease in the daily production of saliva below 500 mL/day is termed hypossecretion or hyposialia.\textsuperscript{7} Sialorrhea, hypersialia, hypersalivation, and ptyalism are terms used to describe salivary flow above the limits of the normal.\textsuperscript{8}

Saliva plays a central role in oral health monitoring, regulating and maintaining the integrity of the oral hard and soft tissues.\textsuperscript{1} It lubricates and cleans the oral cavity, possesses antibacterial, antiviral, and antifungal properties, buffers the pH, helps in chewing, speech, swallowing, and digestion, promotes taste, and contributes to the maintenance and remineralization of teeth.\textsuperscript{9} Moreover, it may be useful in the diagnosis of various diseases.\textsuperscript{10} The characterization by proteomic approaches—of more than 1000 salivary proteins and peptides—has allowed the identification of new salivary markers in oncology, salivary gland dysfunction, Sjögren’s syndrome, systemic sclerosis, psychiatric and neurological diseases, and dental and periodontal pathology.\textsuperscript{11–13}

1.2 INFECTION TRANSMISSION BY SALIVA AND KISSING

The infectivity of microorganisms can depend on the infective load, virulence, with some, such as the notorious norovirus, being extremely contagious and able to survive weeks on surfaces and fomites.\textsuperscript{14} The detection and continuous shedding of infectious agents in saliva does not necessarily mean transmission by this route. Factors including the microorganism load, the existence of specific receptors on oral
epithelial cells, and host defenses may play an important defensive role. Moreover, blood contamination in saliva—often invisible to the eye—is not uncommon mainly among active smokers and individuals with poor oral health status, those with gingivitis or periodontitis, and those with certain infectious diseases including human immunodeficiency virus (HIV) infection.

Saliva contact can cause overt concern when using utensils such as cutlery or oral health devices, or if kissing a person with an infectious disease. However, the apparent absence of obvious disease does not guarantee the absence of infection or infective agents in saliva (or other body fluids): many diseases (especially viral) can be incubating or be subclinical (causing no or nonspecific symptoms or signs). Intimate mucosal contacts, particularly where there are epithelial breaches or substances that may impede salivary defenses (e.g., other body fluids), predispose to infection transmission.

Kissing is not exclusive to humans or primates, though it may have different connotations in different species. Theories to explain kissing behavior consider it to have an origin in social and sexual interactions, premastication of foods for newborns or even the intentional transfer of microorganisms to promote immunity. Kissing is seen in most human cultures, and often is part of daily behavior, playing important roles in building and maintaining interpersonal relationships and in partner selection. There are, however, huge intercultural differences related to kissing; this being considered an acceptable behavior in some cultures but totally offensive in others. For example, social kissing is an accepted form of salutation in the Mediterranean and Latin cultures, in Muslim-majority societies governed by religious law there are strict taboos about whom one can kiss, or people from some areas in Sudan refuse to kiss because they fear having their soul stolen through kissing. In general, kissing is considered by many of the public to have few or no serious health implications.

Different types of kissing are evident and the type of kissing may well be relevant with respect to the transmission of microorganisms, as it not only determines the capacity of the kiss to spread infectious diseases, but it can also have a bearing on the chemoprophylaxis strategy to be used in “kissing contacts” in certain situations (e.g., during an outbreak of meningococcal disease).
“Air kissing” is a cheek-to-cheek approximation; “osculum” is when the lips make contact with the body, usually the cheeks; “basium kiss” consists of mutual approximation of the lips with the mouth closed, exercising light pressure; and finally, there is the “saviolum kiss” in which, in addition to lip contact, the tongue is inserted into the opposite person’s mouth (“French kissing,” “passionate kissing,” “deep kissing,” “active kissing,” or “intimate kissing”). Finally “kiss of life” refers to direct, intense, and recurrent lip contact during mouth-to-mouth resuscitation—the therapy of choice for cardiorespiratory arrest in the community.

Couples may exchange an average of 5 mL of saliva during active kissing, making this an activity that could favor the transmission of infectious diseases. Evidence for person-to-person transmission by kissing is limited to a few microorganisms and even this evidence can be often based on only weak scientific evidence. Published studies are heterogeneous, from isolated case reports of kissing as a “possible” cause of transmission of diseases (e.g., HIV infection) to studies analyzing the inhibitory activity of the saliva on specific microorganisms (e.g., herpes simplex). Few studies have been designed specifically to demonstrate the degree of infectivity if any of kissing, but one study showed it does not efficiently spread common cold infection by Rhinoviruses.

Studies on the risks from mouth-to-mouth ventilation without barrier devices demonstrated isolated cases of transmission of tuberculosis, herpes simplex infection, shigellosis, salmonellosis, and meningococcal infection.

Despite this, evidence for infection transmission by kissing is not strong, so this does not justify philemaphobia (morbid fear of kissing). Paradoxically, it has even been suggested that kissing could be an evolutionary adaptation to protect against some neonatal infections (e.g., cytomegalovirus). In reality, saliva may also have a protective role, and many animals, even humans, instinctively lick wounds—an act that may be defensive—possibly via histatins mainly. Saliva also contains an array of factors which facilitate protection (Table 1.1).

1.3 THE PROTECTIVE ROLE OF SALIVA

Adequate salivary flow has a cleansing action and saliva also contains potentially protective constituents (Table 1.1). Antimicrobial
proteins can arise from epithelial cells, innate immune, and other cells and can modulate the microbial flora in the mouth. For example, viruses such as *noroviruses* are affected by host genetic factors including histoblood group antigens (HBGAs) (i.e., the ABO blood group, the Lewis phenotype, and the secretor status).

Salivary proteins which can be protective at least against certain agents, include scavenger receptor cysteine-rich glycoprotein 340 (salivary gp-340), mucins, histatins, and human neutrophil defensins. The protein gp340—formerly salivary agglutinin—aggregates a variety of bacteria and can function as a specific inhibitor of HIV-1 and influenza A. Salivary mucins MUC5B and MUC7 reduce the attachment and biofilm formation of *Streptococcus mutans* by keeping bacteria in the planktonic state. Several studies have shown that salivary mucins induce phenotypic changes in *Candida albicans* at the level of mRNA transcription, which downregulate genes necessary for hyphal development and some virulence factors. Saliva also contains an array of other protective proteins including tissue factor, growth factors—

| Table 1.1 Antimicrobial Factors in Saliva |
|-----------------------------------------|
| **Factor** | **Antibacterial** | **Antiviral** | **Main details** |
| Agglutinins | + | + | gp340, DMBT1 (deleted in malignant brain tumors 1) |
| Antibodies | + | + | slgA (secretory Immunoglobulin A) |
| Calgranulin or calprotectin | + | − | Calgranulin A/B is antimicrobial by binding calcium and other metals |
| Cathelicidin | + | + | Cathelicidin is cleaved into the antimicrobial peptide LL-37 by both kallikrein 5 and kallikrein 7 serine proteases |
| Cystatin | + | + | A cysteine proteinase inhibitor which can be antiviral |
| Defensins | + | + | HNPs (Human Neutrophil Peptides) α,β |
| Histatins | + | − | A family of histidine-rich antimicrobial proteins, especially antifungal |
| Lactoferrin | + | + | An iron-binding glycoprotein in saliva and various other secretory fluids |
| Lysozyme (muraminidase) | + | − | Damages bacterial cell walls |
| Mucins | + | + | Glycoconjugates (glycosylated proteins) produced by epithelia. Membrane-associated mucins may also act as cell surface receptors for pathogens |
| Peroxidase | + | + | Produced mainly by parotid gland |
| Secretory leukocyte protease inhibitor | + | + | SLPI is found in saliva and many other secretions, protects epithelial tissues from serine proteases, and is antimicrobial |
especially Secretory Leukocyte Protease Inhibitor (SLPI) and Epidermal Growth Factor—which may in addition, facilitate wound healing.  

It has been reported that saliva inhibits oral transmission of HIV through kissing, dental treatment, biting, and aerosolization; both crude saliva and mucins MUC5B and MUC7 inhibit HIV-1 activity, probably because they trap or aggregate the virus and prevent its entry into host cells. SLPI is also important. Hantaviruses are also sensitive to the antiviral actions of mucins, and sialic acid type molecules have high activity against human influenza viruses.  

Histatins provide the first line of defense against C. albicans and other fungi. Cystatin may inhibit coronaviruses. Moreover, saliva mediates antibody-dependent cell-mediated cytotoxicity as in HIV-1-infected individuals and can regulate specific humoral defense mechanisms against microorganisms including Cryptococcus neoformans or Paracoccidioides.  

Oral carriage of microorganisms and infections are more likely where there is hyposalivation and/or immunoincompetence—and so infections may be more prevalent in neonates who lack acquired immunity, or where immunity wanes such as in older or patients with immunocompromising conditions (e.g., malignant disease and its treatment, HIV/AIDS, or corticosteroid therapy)—particularly where the load of infecting agents is high or the microbe is virulent.  

• **Specific saliva protection against oral bacteria**  

Saliva has a mechanical flushing action and there are innate immune defenses and complex interactions with microorganisms. For example, the gene DMBT1 (Deleted in Malignant Brain Tumor 1) encodes antimicrobial proteins involved in mucosal innate immunity, and salivary DMBT1 glycoprotein (gp340) and salivary agglutinin (DMBT1(SAG)) glycoproteins which are identical, agglutinate S. mutans and some other Gram-positive bacteria, as well as several Gram-negative bacteria. Some of the salivary components can change with disease; e.g., higher interleukin (IL)-6/IL-1β, secretory IgA, and lower lysozyme, and histatins 1 and 5 have been found in hepatic cirrhosis. The innate and acquired immune defenses in saliva persist even after removal of lymphoid tissue in tonsillectomy: serum-derived
antimicrobial proteins (myeloperoxidase, lactoferrin, IgG) remain in high concentrations in whole saliva with no effect on the numbers of oral cariogenic *S. mutans* or on the total aerobic flora.  

- **Specific saliva protection against bacteria such as *Pseudomonas aeruginosa***

*Pseudomonas aeruginosa* often colonizes the airways in cystic fibrosis. *P. aeruginosa* binds to oral and bronchial epithelial cells, by pili and fimbriae which promote adherence to glycosphingolipid adhesins asialo-GM1 on surfaces of host epithelia and phagocytes such as polymorphonuclear leukocytes. Failure to isolate pathogenic organisms consistently from the upper airways in all patients with positive sputum argues against a local epithelial factor predisposing to bacterial colonization and also suggests that defensive processes are in play. *P. aeruginosa* are aggregated by saliva.

The sero-mucous products of the submandibular gland have a greater role than the serous secretions of the parotids and are possibly responsible for the differences in oral colonization by *P. aeruginosa* in different subjects. The low-molecular-weight mucin (MG2) of human submandibular—sublingual saliva, and neutral cystatin, bind to pili. *P. aeruginosa* interactions with *S. aureus* may be predicated on the formation of MG2—secretory IgA antibody complex, which may facilitate clearance from the oral cavity.

Interbacterial adherence between strains of *P. aeruginosa* with oral *Actinomyces viscosus* indigenous to the human mouth and with strains of *Streptococcus pyogenes*, and *Streptococcus agalactiae*, appear to involve galactosyl-binding adhesins. Most oral *viridans streptococci* have potentially bacteriocin-like activity against *P. aeruginosa*.

- **Specific saliva protection against viruses such as HIV***

Saliva may also be inhibitory to HIV. Though complete inactivation may require 30 minutes of exposure, saliva may inhibit HIV-1. A main protective mechanism of saliva may be the inactivation of HIV-transmitting leukocytes by the hypotonicity of saliva and the oral transmission of HIV by seminal and other fluids introduced into the mouth may be due to their isotonicity overcoming the inactivation of HIV by isotonic saliva. HIV transmission across mucosae involves complex mechanisms and the oral mucosal epithelia mucosa is less permissive for HIV replication than other sites (e.g., vagina/cervix and anal/rectal). Innate immunity plays a role in protection. Viral reception appears to involve both CD4 (Cluster of Differentiation 4) and a co-receptor—particularly CCR5
The MHC appears to have a role in HIV-1 control, particularly the HLA Complex P5 (HCP5) and Human Leukocyte Antigen-C (HLA-C) and this may explain the occurrence of “Elite Supressor” patients.\(^\text{82}\)

The scavenger receptor protein gp340—encoded by the DMBT1 gene—interacts with surfactant proteins (SP-D), and both gp340 and SP-D can individually and together interact and agglutinate some viruses and DMBT1(gp340) binds to a variety of other host proteins, including serum and secretory IgA, C1q, lactoferrin, MUC5B, and Trefoil Factor 2 (TFF2), all molecules involved in innate immunity and/or wound healing.\(^\text{57}\)

The protein gp340 appears to facilitate HIV transmission across genital but not oral mucosa.\(^\text{83–86}\) Acquired immunity might confer some protection in re-exposures: immunization with an HIV peptide may produce HIV-inhibitory antibodies in saliva.\(^\text{87}\)

Various glycoproteins may also be inhibitory to HIV. Crude saliva and salivary mucins MUC5B and MUC7 (both from HIV-positive people and uninfected controls) can inhibit HIV-1.\(^\text{46,88}\) Other glycoproteins may also be implicated.\(^\text{89,90}\)

SLPI may have an important HIV-inhibitory role,\(^\text{91,92}\) as might human \(\beta\)-defensins (hBDs) from the epithelium.\(^\text{93,94}\) Saliva may also mediate antibody-dependent cytotoxicity against HIV.\(^\text{52}\)

- **Specific saliva protection against influenza A virus**
  Other viruses as, e.g., H5N1 influenza virus are particularly susceptible to human saliva, which may play a role in its infectivity and transmissibility.\(^\text{48}\)

  Many salivary antibacterial proteins have antiviral activity, typically against specific pathogens.\(^\text{41}\) Antiviral activities of saliva against influenza A virus (IAV) and HIV differ both in terms of specific glandular secretions and the inhibitory proteins. Whole saliva or parotid or submandibular/sublingual secretions from healthy donors inhibits IAV, whereas only submandibular/sublingual secretions are inhibitory to HIV. Among salivary proteins, scavenger receptor cysteine-rich glycoprotein 340 (gp340), MUC5B, histatins, and human neutrophil defensins at concentrations present in whole saliva inhibit IAV, while acidic proline-rich proteins and amylase have no activity nor do several less abundant salivary proteins (e.g., thrombospondin or serum SLPI).\(^\text{95}\)

  gp340 interacts with surfactant proteins A and D (SP-D) and can interact and agglutinate IVA virus and also binds to proteins (Chemokine Receptor type 5).\(^\text{81}\)
involved in innate immunity and/or wound healing, including serum and secretory IgA, C1q, lactoferrin, MUC5B and TFF2. Salivary gp340 can antagonize SP-D antiviral activities—which may be relevant to the effects of aspiration of oral contents on SP-D-mediated lung functions.

Other components responsible for antiviral activity on influenza virus, in particular swine origin influenza A virus (S-OIV), include an α-2-macroglobulin (A2M) and an A2M-like protein. Salivary glycoproteins which have significant roles against IVA also include lectins (e.g., MAL-II and SNA).

MUC5B inhibits IAV by presenting a sialic acid ligand for the viral hemagglutinin. Other sialic acid–containing molecules may be effective against human influenza viruses more so than against H5N1.

- **Specific saliva protection against fungi such as Candida spp.**

  Both innate immunity and cell-mediated immune response are involved in defenses against fungal infections. Saliva has a mechanical defense action and components including secretory immunoglobulin A, lactoferrin, and polymorphonuclear leukocyte (PMNL) superoxide are protective. A low, stimulated salivary flow rate—not a low, unstimulated flow rate—is associated with Candida spp. carriage.

  Salivary components mediate microbial attachment to oral surfaces and interact with planktonic microbial surfaces to facilitate agglutination often mediated by lectin-like proteins that bind to glycan motifs on salivary glycoproteins and help eliminate pathogens. Antimicrobial peptides in saliva appear to play a crucial role in the regulation of oral Candida growth. Oral candidiasis may be associated with salivary gland hypofunction and decreases of salivary lactoferrin, secretory immunoglobulin A, β-defensin 1, and β-defensin 2 antibacterial proteins.

Histatins are basic histidine-rich cationic proteins present in saliva that provide the first line of defense against oral candidiasis—an important antimicrobial is histatin 5 (Hst 5), which shows potent and selective antifungal activity and with the carrier molecule spermidine which, by binding to fungal cell wall proteins (Ssa1/2) and glycans, significantly enhances C. albicans killing. Histatins effectively kill C. albicans, C. glabrata, and C. Krusei, and histatin 3 acts against C. dubliniensis.
Other antimicrobial proteins include calprotectin,\textsuperscript{105} cystatin SA1,\textsuperscript{106} and $\beta$-defensin 2,\textsuperscript{107} deficiencies of which predispose to chronic candidiasis. Salivary lysozyme can also be protective.\textsuperscript{108}

The development of candidiasis in HIV-infected patients could be a consequence of inefficient lysozyme and lactoferrin concentrations and of decreased cooperation between innate and adaptive immune systems.\textsuperscript{109} The vast majority of Candida isolates appear to succumb to nonspecific host immune mediators,\textsuperscript{110} but innate immunity alone is unable to stop yeast expansion in HIV-infected patients.\textsuperscript{111}

\textit{C. albicans}-secreted aspartyl proteinase (SAP1-SAP8) and phospholipase B (PLB1 and PLB2) genes are expressed during both infection and carriage of Candida spp. The differential expression of these hydrolytic enzyme genes correlates the expression of specific Candida spp. virulence genes with active candidiasis and anatomical location.\textsuperscript{112} Salivary anti-somatic, anti-SAP2, and anti-SAP6 antibodies are not efficient in limiting candidal infection\textsuperscript{113} and although HIV-infected patients have a high mucosal response against \textit{C. albicans} virulence antigens, such as somatic antigen, Sap1, and Sap6,\textsuperscript{114} this is not totally protective.

Defensins such as $\alpha$-defensin (Human Neutrophil Peptides, HNPs) and $\beta$-defensin-2 (hBD-2) peptides can have antifungal and cytotoxic activities.\textsuperscript{115} Defensins that exhibit antibacterial, antifungal, and antiviral properties are a component of the innate immune response. $\beta$-defensins (hBD-1) are cationic antimicrobial peptides encoded by the DEFB1 gene expressed in oral epithelia that may have a major role in mediating and/or contributing to susceptibility to candidiasis.\textsuperscript{116}

Nitric oxide (NO) is involved in host resistance to infection with \textit{C. albicans} at least in animal models. IL-4 is associated with resistance to oral candidiasis and suggests that NO is involved in controlling colonization of the oral mucosal surface with \textit{C. albicans}.\textsuperscript{117}

Oral epithelial cells may play a role in innate resistance against candidiasis.\textsuperscript{118} Host defenses against \textit{C. albicans} include epithelial cell defenses and innate and specific immune mechanisms. Cell-mediated immunity by Th1-type CD4+ T-cells is important for protection against mucosal infections, and PMNLs are important for protection against systemic infections.\textsuperscript{119} When CD8(+) T-cell migration is
inhibited by reduced tissue E-cadherin, there is susceptibility to infection which supports a role for CD8(+) T cells in host defense against oropharyngeal candidiasis.\textsuperscript{120}

Fungal pattern recognition receptors such as C-type lectin receptors trigger protective T-helper (Th)17 responses in the oral mucosa. The Th17/IL-17 axis is vital for immunity to fungi, especially \textit{C. albicans}. The inflammatory cytokine IL-17 induces tumor necrosis factor (TNF)-α, and interleukins IL-1β and IL-6.\textsuperscript{121} A systemic immune response involving T-helper 1 (Th1) cells with the production of TNF-α and IFN-γ is seen in patients with oral candidiasis.\textsuperscript{122} Th17 cells may act through IL-17, to confer defenses via neutrophils and antimicrobial factors.\textsuperscript{123} Oral epithelial cells also are involved in local host defenses against \textit{C. albicans} infections via IFN-γ induced IL-18.\textsuperscript{124}

Biofilms, some 15% of which may be due to dual \textit{Candida} spp., contribute to the pathogenesis of oral candidiasis,\textsuperscript{125} biofilm formation of \textit{C. albicans} appearing to be modulated by salivary and dietary factors.\textsuperscript{126}

\textit{C. albicans} hyphal wall protein 1 (Hwp1) mRNA is present in candidiasis regardless of symptoms, implicating hyphal and possibly pseudohyphal forms in mucosal carriage as well as disease.\textsuperscript{127} Overall, Hwp1 and hyphal growth forms appear to be important factors in both benign and invasive interactions of \textit{C. albicans} with human hosts.

1.4 PREVENTION OF TRANSMISSION OF MICROORGANISMS BY SALIVA

Transmission of infection by saliva may be prevented or minimized by avoidance of exposure, by good oral hygiene (plaque removal), and by the use of the various substances such as some mouthwashes, and probiotics that may inhibit salivary microorganisms.\textsuperscript{128,129}

1.5 CLOSING REMARKS AND PERSPECTIVES

Bacterial pathogens have been identified in salivary samples by specific antibody reactivity, antigen detection, or via PCR, including \textit{Escherichia coli}, \textit{Mycobacterium tuberculosis}, \textit{Treponema pallidum}, and a wide range of \textit{Streptococcus} spp. More than 20 viruses have also been detected; these include a number of \textit{Herpes viruses}, \textit{Hepatitis viruses}, \textit{Human Immunodeficiency Viruses}, \textit{Papillomavirus}, \textit{Influenza
virus, or Poliovirus. Nonviral and nonbacterial infectious agents including fungi and protozoa are also detectable, usually by antibodies to these infectious agents. Recognition of the components of the oral microbiota can help in the prediction of the onset, progression, and prognosis of oral and systemic diseases. Tests for these pathogens are currently under development. Omics methods, such as 16S rRNA sequencing, metagenomics, and metabolomics, can play an essential role to explore microbial community and its metabolite production, without the biases of microbial culture. Saliva contains many antibacterial, antiviral, and antifungal agents which modulate the oral microbial flora. Consequently, detection and shedding of infectious agents in saliva does not necessarily mean transmission by this route. Anyway, the presence of these pathogens in saliva is particularly important in immunosuppressed patients in whom infections can result fatal. Moreover, the defensive ability of saliva against emerging infectious diseases caused by new or previously unrecognized microorganisms remains unknown.

REFERENCES
1. Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000;50(3):140–61.
2. Roth GI, Calmes RB. Salivary glands and saliva. In: Roth GI, Calmes RB, editors. Oral biology. St. Louis, MO: Mosby; 1981. p. 196–236.
3. Edgar WM. Saliva: its secretion, composition and functions. Br Dent J 1992;172(8):305–12.
4. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 2002;8(3):117–29.
5. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Phys 2004;69(11):2628–34.
6. Proctor GB, Carpenter GH. Salivary secretion: mechanism and neural regulation. Monogr Oral Sci 2014;24:14–29.
7. Jenkins G. Saliva. In: Jenkins GN, editor. The physiology and biochemistry of the mouth. 4th ed. Oxford: Blackwell Scientific Publications; 1978. p. 284–359.
8. Scully C, Limeres J, Gleeson M, Tomas I, Diz P. Drooling. J Oral Pathol Med 2009;38(4):321–7.
9. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987;66:648–53 Spec No
10. Malamud D. Saliva as a diagnostic fluid. BMJ 1992;305(6847):207–8.
11. Castagnola M, Picciotti PM, Messana I, et al. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital 2011;31(6):347–57.
12. Nunes LA, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem Med (Zagreb) 2015;25(2):177–92.
13. Podzimek S, Vondrackova L, Duskova J, Janatova T, Broukal Z. Salivary markers for periodontal and general diseases. *Dis Markers* 2016;2016:9179632
14. Goodgame R. Norovirus gastroenteritis. *Curr Gastroenterol Rep* 2006;8(5):401–8.
15. Ferreiro MC, Dios PD, Scully C. Transmission of hepatitis C virus by saliva? *Oral Dis* 2005;11(4):230–5.
16. Kim YJ, Kim YK, Kho HS. Effects of smoking on trace metal levels in saliva. *Oral Dis* 2010;16(8):823–30.
17. Kamodyova N, Banasova L, Jansakova K, et al. Blood contamination in saliva: impact on the measurement of salivary oxidative stress markers. *Dis Markers* 2015;2015:479251
18. Piazza M, Chirianni A, Picciotto L, Cataldo PT, Borgia G, Orlando R. Blood in saliva of patients with acquired immunodeficiency syndrome: possible implication in sexual transmission of the disease. *J Med Virol* 1994;42(1):38–41.
19. de Waal FB. Primates—a natural heritage of conflict resolution. *Science* 2000;289(5479):586–90.
20. Kirshenbaum S. *The science of kissing: what our lips are telling us*. Hachette, UK: Grand Central Publishing; 2011.
21. Hughes SM, Harrison MA, Gallup GG. Sex differences in romantic kissing among college students: an evolutionary perspective. *Evol Psychol* 2007;5(3):612–31.
22. Wlodarski R, Dunbar RI. What’s in a kiss? The effect of romantic kissing on mating desirability. *Evol Psychol* 2014;12(1):178–99.
23. Wlodarski R, Dunbar RI. Examining the possible functions of kissing in romantic relationships. *Arch Sex Behav* 2013;42(8):1415–23.
24. Poyatos F. Kinesics: gesturers, manners and postures. In: Poyatos F, editor. *Nonverbal communication across disciplines: Volume 2: Paralanguage, kinesics, silence, personal and environmental interaction*. Amsterdam: John Benjamins Publishing; 2002. p. 216–30.
25. Willmott FE. Transfer of gonococcal pharyngitis by kissing? *Br J Vener Dis* 1974;50(4):317–18.
26. Hayward A. Carriage of meningococci in contacts of patients with meningococcal disease. “Kissing contacts” need to be defined. *BMJ* 1999;318(7184):665.
27. Touyz L. Lips, kissing and oral implications. *J Aesthet Dent* 2009;3(5):29–34.
28. Woolley R. The biologic possibility of HIV transmission during passionate kissing. *JAMA* 1989;262(16):2230.
29. Anonymous. Kissing reported as possible cause of HIV transmission. *J Can Dent Assoc* 1997;63(8):603.
30. Mikola H, Waris M, Tenovuo J. Inhibition of herpes simplex virus type 1, respiratory syncytial virus and echovirus type 11 by peroxidase-generated hypothiocyanite. *Antiviral Res* 1995;26(2):161–71.
31. D’Alessio DJ, Meschievitz CK, Peterson JA, Dick CR, Dick EC. Short-duration exposure and the transmission of rhinoviral colds. *J Infect Dis* 1984;150(2):189–94.
32. Giammaria M, Frittelli W, Belli R, et al. Does reluctance to perform mouth-to-mouth ventilation exist among emergency healthcare providers as first responders?. *Ital Heart J Suppl* 2005;6(2):90–104.
33. Heilman KM, Muschenheim C. Primary cutaneous tuberculosis resulting from mouth-to-mouth respiration. *N Engl J Med* 1965;273(19):1035–6.
34. Hendricks AA, Shapiro EP. Primary herpes simplex infection following mouth-to-mouth resuscitation. *JAMA* 1980;243(3):257–8.
35. Todd MA, Bell JS. Shigellosis from cardiopulmonary resuscitation. *JAMA* 1980;243(4):331.
36. Ahmad F, Senadhira DC, Charters J, Acquilla S. Transmission of *Salmonella* via mouth-to-mouth resuscitation. *Lancet* 1990;335(8692):787–8.
37. Feldman HA. Some recollections of the meningococcal diseases. The first Harry F. Dowling lecture. *JAMA* 1972;220(8):1107–12.
38. Hendrie CA, Brewer G. Kissing as an evolutionary adaptation to protect against human cytomegalovirus-like teratogenesis. *Med Hypotheses* 2010;74(2):222–4.
39. Oudhoff MJ, Bolscher JG, Nazmi K, et al. Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay. *FASEB J* 2008;22(11):3805–12.
40. Brand HS, Ligtenberg AJ, Veerman EC. Saliva and wound healing. *Monogr Oral Sci* 2014;24:52–60.
41. Malamud D, Abrams WR, Barber CA, Weissman D, Rehtanz M, Golub E. Antiviral activities in human saliva. *Adv Dent Res* 2011;23(1):34–7.
42. Dawes C, Pedersen AM, Villa A, et al. The functions of human saliva: a review sponsored by the world workshop on oral medicine VI. *Arch Oral Biol* 2015;60(6):863–74.
43. Le Pendu J, Nystrom K, Ruvoen-Clouet N. Host-pathogen co-evolution and glycan interactions in human saliva. *Curr Opin Virol* 2014;4:89–94.
44. Baughan LW, Robertello FJ, Sarrett DC, Denny PA, Denny PC. Salivary mucin as related to oral *Streptococcus mutans* in elderly people. *Oral Microbiol Immunol* 2000;15(1):10–14.
45. Kavanaugh NL, Zhang AQ, Noble CI, Johnson AD, Ribbeck K. Mucins suppress virulence traits of *Candida albicans*. *MBio* 2014;5(6):e01911–14.
46. Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of human immunodeficiency virus type 1 in an inhibition assay. *Virol J* 2006;3:99.
47. Hardestam J, Petterson L, Ahlm C, Evander M, Lundkvist A, Klingstrom J. Antiviral effect of human saliva against hantavirus. *J Med Virol* 2008;80(12):2122–6.
48. Limsuwat N, Suptawiwat O, Boonarkart C, Puthavathana P, Wiriyarat W, Auewarakul P. Sialic acid content in human saliva and anti-influenza activity against human and avian influenza viruses. *Arch Virol* 2016;161(3):649–56.
49. Puri S, Edgerton M. How does it kill? Understanding the candidacidal mechanism of salivary histatin 5. *Eukaryot Cell* 2014;13(8):958–64.
50. Hanasab H, Jammal D, Oppenheim FG, Helmerhorst EJ. The antifungal activity of human parotid secretion is species-specific. *Med Mycol* 2011;49(2):218–21.
51. Collins AR, Grubb A. Cystatin D, a natural salivary cysteine protease inhibitor, inhibits coronavirus replication at its physiologic concentration. *Oral Microbiol Immunol* 1998;13(1):59–61.
52. Kim HN, Meier A, Huang ML, et al. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. *J Infect Dis* 2006;194(4):420–7.
53. Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of *Cryptococcus neoformans*. *J Infect Dis* 1966;116(1):75–83.
54. Miura CS, Estevao D, Lopes JD, Itano EN. Levels of specific antigen (gp43), specific antibodies, and antigen-antibody complexes in saliva and serum of paracoccidioidomycosis patients. *Med Mycol* 2001;39(5):423–8.
55. Scannapieco FA. Saliva-bacterium interactions in oral microbial ecology. *Crit Rev Oral Biol Med* 1994;5(3-4):203–48.
56. Marsh PD, Do T, Beighton D, Devine DA. Influence of saliva on the oral microbiota. *Periodontal 2000* 2016;70(1):80–92.
57. Madsen J, Mollenhauer J, Holmskov U. Review: Gp-340/DMBT1 in mucosal innate immunity. *Innate Immun* 2010;16(3):160–7.

58. Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. *Hepatology* 2015;62(4):1260–71.

59. Lenander-Lumikari M, Tenovuo J, Puhakka HJ, et al. Salivary antimicrobial proteins and mutants streptococci in tonsillectomized children. *Pediatr Dent* 1992;14(2):86–91.

60. Baker N, Hansson GC, Leffler H, Riise G, Svanborg-Eden C. Glycosphingolipid receptors for *Pseudomonas aeruginosa*. *Infect Immun* 1990;58(7):2361–6.

61. Canullo L, Rossetti PH, Penarrocha D. Identification of *Enterococcus faecalis* and *Pseudomonas aeruginosa* on and in implants in individuals with peri-implant disease: a cross-sectional study. *Int J Oral Maxillofac Implants* 2015;30(3):583–7.

62. Paranchych W, Sastry PA, Volpel K, Loh BA, Speert DP. Fimbriae (pili): molecular basis of *Pseudomonas aeruginosa* adherence. *Clin Invest Med* 1986;9(2):113–18.

63. Doig P, Paranchych W, Sastry PA, Irvin RT. Human buccal epithelial cell receptors of *Pseudomonas aeruginosa*: identification of glycoproteins with pilus binding activity. *Can J Microbiol* 1989;35(12):1141–5.

64. Doig P, Sastry PA, Hodges RS, Lee KK, Paranchych W, Irvin RT. Inhibition of pilus-mediated adhesion of *Pseudomonas aeruginosa* to human buccal epithelial cells by monoclonal antibodies directed against pili. *Infect Immun* 1990;58(1):124–30.

65. Taylor CJ, McGaw J, Howden R, Duerden BI, Baxter PS. Bacterial reservoirs in cystic fibrosis. *Arch Dis Child* 1990;65(2):175–7.

66. Komiyama K, Habbick BF, Tumber SK. Whole, submandibular, and parotid saliva-mediated aggregation of *Pseudomonas aeruginosa* in cystic fibrosis. *Infect Immun* 1989;57(4):1299–304.

67. Reddy MS. Binding of the pili of *Pseudomonas aeruginosa* to a low-molecular-weight mucin and neutral cystatin of human submandibular-sublingual saliva. *Curr Microbiol* 1998;37(6):395–402.

68. Biesbrock AR, Reddy MS, Levine MJ. Interaction of a salivary mucin-secretory immunoglobulin A complex with mucosal pathogens. *Infect Immun* 1991;59(10):3492–7.

69. Komiyama K, Gibbons RJ. Interbacterial adherence between *Actinomyces viscosus* and strains of *Streptococcus pyogenes*, *Streptococcus agalactiae*, and *Pseudomonas aeruginosa*. *Infect Immun* 1984;44(1):86–90.

70. Uehara Y, Kikuchi K, Nakamura T, et al. H(2)O(2) produced by viridans group streptococci may contribute to inhibition of methicillin-resistant staphylococcus aureus colonization of oral cavities in newborns. *Clin Infect Dis* 2001;32(10):1408–13.

71. Fultz PN. Components of saliva inactivate human immunodeficiency virus. *Lancet* 1986;2(8517):1215.

72. Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. Saliva inhibits HIV-1 infectivity. *J Am Dent Assoc* 1988;116(6):635–7.

73. Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men, women, and children. *J Am Dent Assoc* 1989;118(6):709–11.

74. Archibald DW, Cole GA. In vitro inhibition of HIV-1 infectivity by human salivas. *AIDS Res Hum Retroviruses* 1990;6(12):1425–32.

75. Moore BE, Flaitz CM, Coppenhaver DH, et al. HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. *J Am Dent Assoc* 1993;124(10):67–74.

76. Robinovitch MR, Iversen JM, Resnick L. Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. *Crit Rev Oral Biol Med* 1993;4(3-4):455–9.
Baron S, Poast J, Cloyd MW. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. *Arch Intern Med* 1999;159(3):303–10.

Baron S, Poast J, Richardson CJ, Nguyen D, Cloyd M. Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: a novel mechanism. *J Infect Dis* 2000;181(2):498–504.

Tebit DM, Ndembi N, Weinberg A, Quinones-Mateu ME. Mucosal transmission of human immunodeficiency virus. *Curr HIV Res* 2012;10(1):3–8.

Nittayananta W, Weinberg A, Malamud D, Moyes D, Webster-Cyriaque J, Ghosh S. Innate immunity in HIV-1 infection: epithelial and non-specific host factors of mucosal immunity- a workshop report. *Oral Dis* 2016;22(Suppl. 1):171–80.

Clapham PR, McKnight A. HIV-1 receptors and cell tropism. *Br Med Bull* 2001;58(1):43–59.

Han Y, Lai J, Barditch-Crovo P, et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. *AIDS* 2008;22(4):541–4.

Wu Z, Lee S, Abrams W, Weissman D, Malamud D. The N-terminal SRCR-SID domain of gp-340 interacts with HIV type 1 gp120 sequences and inhibits viral infection. *AIDS Res Hum Retroviruses* 2006;22(6):508–15.

Cannon G, Yi Y, Ni H, et al. HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. *J Immunol* 2008;181(3):2065–70.

Stoddard E, Ni H, Cannon G, et al. Gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. *J Virol* 2009;83(17):8396–603.

Patyka M, Malamud D, Weissman D, Abrams WR, Kurago Z. Periluminal distribution of HIV-binding target cells and Gp340 in the oral, cervical and sigmoid/rectal mucosae: a mapping study. *PLoS One* 2015;10(7):e0132942.

Bukawa H, Sekigawa K, Hamajima K, et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. *Nat Med* 1995;1(7):681–5.

Peacocke J, Lotz Z, de Beer C, Roux P, Mall AS. The role of crude saliva and purified salivary mucins in the inhibition of the human immunodeficiency virus type 1. *Virol J* 2012;9:177.

Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva. *J Exp Med* 1998;187(1):25–35.

Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. *J Infect Dis* 1998;178(6):1635–41.

McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. *J Clin Invest* 1995;96(1):456–64.

McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. *Blood* 1997;90(3):1141–9.

Sun L, Finnegan CM, Kish-Catalone T, et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. *J Virol* 2005;79(22):14318–29.

Weinberg A, Quinones-Mateu ME, Lederman MM. Role of human beta-defensins in HIV infection. *Adv Dent Res* 2006;19(1):42–8.
95. White MR, Helmerhorst EJ, Ligtenberg A, et al. Multiple components contribute to ability of saliva to inhibit influenza viruses. *Oral Microbiol Immunol* 2009;24(1):18–24.

96. Hartshorn KL, Ligtenberg A, White MR, et al. Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation. *Biochem J* 2006;393(Pt 2):545–53.

97. Chen CH, Zhang XQ, Lo CW, et al. The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus. *Proteomics* 2010;10(12):2396–401.

98. Qin Y, Zhong Y, Zhu M, et al. Age- and sex-associated differences in the glycopatterns of human salivary glycoproteins and their roles against influenza A virus. *J Proteome Res* 2013;12(6):2742–54.

99. Ueta E, Tanida T, Doi S, Osaki T. Regulation of *Candida albicans* growth and adhesion by saliva. *J Lab Clin Med* 2000;136(1):66–73.

100. Radfar L, Shea Y, Fischer SH, et al. Fungal load and candidiasis in Sjogren’s syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003;96(3):283–7.

101. Tanida T, Okamoto T, Okamoto A, et al. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. *J Oral Pathol Med* 2003;32(10):586–94.

102. Nikawa H, Jin C, Makihira S, Hamada T, Samaranayake LP. Susceptibility of *Candida albicans* isolates from the oral cavities of HIV-positive patients to histatin-5. *J Prosthodont Dent* 2002;88(3):263–7.

103. Torres SR, Garzino-Demo A, Meiller TF, Meeks V, Jabra-Rizk MA. Salivary histatin-5 and oral fungal colonisation in HIV + individuals. *Mycoses* 2009;52(1):11–15.

104. Fitzgerald DH, Coleman DC, O’Connell BC. Susceptibility of *Candida dubliniensis* to salivary histatin 3. *Antimicrob Agents Chemother* 2003;47(1):70–6.

105. Sweet SP, Denbury AN, Challacombe SJ. Salivary calprotectin levels are raised in patients with oral candidiasis or Sjogren’s syndrome but decreased by HIV infection. *Oral Microbiol Immunol* 2001;16(2):119–23.

106. Lindh E, Brannstrom J, Jones P, et al. Autoimmunity and cystatin SA1 deficiency behind chronic mucocutaneous candidiasis in autoimmune polyendocrine syndrome type 1. *J Autoimmun* 2013;42:1–6.

107. Conti HR, Baker O, Freeman AF, et al. New mechanism of oral immunology to mucosal candidiasis in hyper-IgE syndrome. *Mucosal Immunol* 2011;4(4):448–55.

108. Lin AL, Johnson DA, Patterson TF, et al. Salivary anticandidal activity and saliva composition in an HIV-infected cohort. *Oral Microbiol Immunol* 2001;16(5):270–8.

109. Laibe S, Bard E, Bichle S, et al. New sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part II: Time-resolved immunofluorometric assay used in HIV patients with oral candidiasis. *Clin Chem Lab Med* 2003;41(2):134–8.

110. Samaranayake YH, Samaranayake LP, Pow EH, Beena VT, Yeung KW. Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential *Candida albicans* isolates from a human immunodeficiency virus-infected southern chinese cohort. *J Clin Microbiol* 2001;39(9):3296–302.

111. Bard E, Laibe S, Clair S, et al. Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. *J Acquir Immune Defic Syndr* 2002;31(3):276–84.

112. Naglik JR, Rodgers CA, Shirlaw PJ, et al. Differential expression of *Candida albicans* secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. *J Infect Dis* 2003;188(3):469–79.
113. Millon L, Drobacheff C, Piarroux R, et al. Longitudinal study of anti-candida albicans mucosal immunity against aspartic proteinases in HIV-infected patients. *J Acquir Immune Defic Syndr* 2001;26(2):137–44.

114. Drobacheff C, Millon L, Monod M, et al. Increased serum and salivary immunoglobulins against *Candida albicans* in HIV-infected patients with oral candidiasis. *Clin Chem Lab Med* 2001;39(6):519–26.

115. Sawaki K, Mizukawa N, Yamaai T, Fukunaga J, Sugahara T. Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. *Oral Dis* 2002;8(1):37–41.

116. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with candida carriage in type I diabetics and nondiabetic controls. *J Clin Microbiol* 2003;41(1):90–6.

117. Elahi S, Pang G, Ashman RB, Claney R. Nitric oxide-enhanced resistance to oral candidiasis. *Immunology* 2001;104(4):447–54.

118. Steele C, Leigh J, Slobodan R, Fidel Jr. PL. Growth inhibition of candida by human oral epithelial cells. *J Infect Dis* 2006;182(5):1479–85.

119. Fidel Jr. PL. Immunity to candida. *Oral Dis* 2002;8(Suppl. 2):69–75.

120. Quimby K, Lilly EA, Zacharek M, et al. CD8 T cells and E-cadherin in host responses against oropharyngeal candidiasis. *Oral Dis* 2012;18(2):153–61.

121. Bishu S, Su EW, Wilkerson ER, et al. Rheumatoid arthritis patients exhibit impaired *Candida albicans*-specific Th17 responses. *Arthritis Res Ther* 2014;16(1):R50.

122. Oliveira MA, Carvalho LP, Gomes Mde S, Bacellar O, Barros TF, Carvalho EM. Microbiological and immunological features of oral candidiasis. *Microbiol Immunol* 2007;51(8):713–19.

123. Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. *J Exp Med* 2009;206(2):299–311.

124. Tardif F, Goulet JP, Zakrzeswski A, Chauvin P, Rouabhia M. Involvement of interleukin-18 in the inflammatory response against oropharyngeal candidiasis. *Med Sci Monit* 2004;10(8):BR239–49.

125. Thein ZM, Samaranayake YH, Samaranayake LP. Characteristics of dual species candida biofilms on denture acrylic surfaces. *Arch Oral Biol* 2007;52(12):1200–8.

126. Jin Y, Samaranayake LP, Samaranayake Y, Yap HK. Biofilm formation of *Candida albicans* is variably affected by saliva and dietary sugars. *Arch Oral Biol* 2004;49(10):789–98.

127. Naglik JR, Fostira F, Ruprai J, Staab JF, Challacombe SJ, Sundstrom P. *Candida albicans* HWP1 gene expression and host antibody responses in colonization and disease. *J Med Microbiol* 2006;55(Pt 10):1323–7.

128. Stecksen-Blicks C, Holgerson PL, Twetman S. Effect of xylitol and xylitol-fluoride lozenges on approximal caries development in high-caries-risk children. *Int J Paediatr Dent* 2008;18(3):170–7.

129. Singh RP, Damle SG, Chawla A. Salivary mutants streptococci and lactobacilli modulations in young children on consumption of probiotic ice-cream containing *Bifidobacterium lactis* Bb12 and lactobacillus acidophilus La5. *Acta Odontol Scand* 2011;69(6):389–94.